|Videos|January 16, 2023
Emerging Data in Non-Clear Cell RCC Treatment
Author(s)Hans Hammers, MD, PhD, Moshe Ornstein, MD
Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR TKI–pretreated advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
4
The OncFive: Top Oncology Articles for the Week of 8/16
5